Two centuries. Countless innovations. One vision.
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union
Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration
Phase 3 Trial of ICLUSIG® (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the US
European Commission (EC) Approves LIVTENCITYTM▼ (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistance) to One or More Prior Therapies
Takeda Delivers Strong FY2022 H1 Results and Raises Full-Year Forecast
SEE ALL NEWS AND RELEASES >
・For Shire news releases, click here
Luck is not a strategy: The world needs to start preparing now for the next pandemic
The COVID-19 Mental Burden on Working Mothers
Takeda Neuroscience at the Annual Meeting of the American Academy of Neurology (AAN) 2021
Takeda Breaks Ground on Commercial Cell Therapy Manufacturing Facility in Lexington, Massachusetts
Spotlight Malawi: Many Paths Towards Universal Health Coverage and a Strong Health Workforce
SEE ALL FEATURED TOPICS ARTICLES >
With this new original series featured in Asahi Shimbun Globe, President & CEO Christophe Weber gives his unique perspective on what he has learned from his upbringing in France and his international career.
For media inquiries or reporter requests for more information, contact our Corporate Communications via Media_Relations@takeda.com. If you generally would like to contact us, please visit Contact Us.
Copyright 1995-2022 Takeda Pharmaceutical Company Limited. All rights reserved.